Member Info for Mikethebat

Who knows how low it will go, the Google Ticker its 0.78 at this moment

I was involved with BAe and new was was coming. I would like to think there is more upward travel in the short distance till they find the right buys, Im still a

You fellow investors, keep an eye on this new boy

In my area (East Midlands) Persimmon,Barrett aqnd Miller are all building like crazy, they must want bricks very soon. I like this share and been in and out as you see from my posts now in again

46p Close, Great

Report Summary: Michelmersh Brick Holdings Plc is an above average quality company with a neutral outlook. Michelmersh Brick Holdings Plc has medium business growth and is run by passable management. When compared to its closest peer, Cookson Group plc, Michelmersh Brick Holdings Plc shows similar undervaluation and is equally likely to outperform the market.

Michelmersh Brick Holdings has won planning permission for the construction of 170 houses on its site at Hadley, Telford. The group is considering a 5m equity issue to raise funds for further development of its landfill sites and other assets. Michelmersh says planning permission from Telford & Wrekin Council marks the first phase of development of 90 acres over the next 10 years in partnership with Persimmon Homes

Long time no chat and SP down today and not doing much but I think its just sit and watch and hey we are out of the recession!!, more house building etc coming.Ennistone,(Ennimix) Breedon Hill all near me and I have a friend who works with Bretts which is still privately owned with places in Kent, Jersey and Leicester

I bought in at 23p so I am staying

These are good products that need good marketing

Time to get in again

Michelmersh is a share worth looking at for 2010 as it worked for me in the last quarter of 09

I see builders licking their lips on potental for 2010, time to get in again on these share

Spitfire Oil Limited announces that it has received notification that Citadel Equity Fund Ltd (“Citadel”) has sold its holding of 16,666,667 ordinary shares in the Company to Griffin Mining Limited (“Griffin”; AIM Ticker: GFM), representing a 39.2% interest in the issued share capital of Spitfire, at 15p per share for cash at a total value of approximately £2,500,000. Following this sale, Citadel has no interest in the share capital of the Company. This was from 2008, but could be interesting for Spitfire soon

Peter Tom who I have known for some 40 years and made his money selling his company to Aggregates for 1.2 Billion, his father had gravel interests in Cornwall and Peter has taken on the mantle. A very very rich man who owns the Leicester Tigers Rugby Club is a shrewd businessman and I wouldnt be surprised to see this company move forward soon

Yes they dipped today but a good company with plenty of land ready to build on

Soon they will all want bricks

Avacta rose 0.3p to 1.62p after the first sale of its flagship product Optim, a bench-top instrument that can analyse tiny drug compounds. When the system, which can cost up to £100,000, was launched in April, the group’s management predicted that sales could generate up to £50 million over five years.

Could this be the origin of the first order

AVACTA GROUP PLC - Re AgreementMonday, September 28, 2009 2:02 AM Email Article Bookmark: TwitterDeliciousDiggYahoo BuzzFacebookStumbleuponLinked InMy SpaceNewsvine Font Size Print Article London, Sep. 28, 2009 (PR Newswire UK Disclose) -- Avacta Group plc Commercialisation of flagship technology - Optim Reducing risk and costs for biopharmaceutical developers Avacta Group plc ("Avacta" or the "Company"), the company providing innovative, high value technologies and services to the pharmaceutical and diagnostics markets, is pleased to announce the first order from a global biopharmaceutical developer for its recently launched flagship product Optim, an analytical technology that is designed to reduce risk in biopharmaceutical development and help drug companies bring optimised products to market quicker and at lower cost. The Directors believe that this is a significant and pivotal step for the Company as it provides validation for its flagship product and a clear demonstration of market demand. Optim fills a significant gap in the market providing detailed analysis using only very small sample volumes. For the first time this enables drug developers to gain vital information about product performance in the early stages of product development, when very limited quantities of material are available, helping to redu